M&A Deal Summary

GPB Capital Acquires Buckeye Water Service

On August 1, 2017, asset manager GPB Capital acquired environmental company Buckeye Water Service

Acquisition Highlights
  • This is GPB Capital’s 3rd transaction in the Environmental sector.
  • This is GPB Capital’s 7th transaction in the United States.
  • This is GPB Capital’s 1st transaction in Ohio.

M&A Deal Summary

Date 2017-08-01
Target Buckeye Water Service
Sector Environmental
Buyer(s) GPB Capital
Deal Type Buyout (LBO, MBO, MBI)

Target

Buckeye Water Service

New Concord, Ohio, United States
Buckeye Water Service Co. provides fluid hauling and storage, oilfield trucking and equipment, roll-off container, and solid waste removal services to customers engaged in drilling and development in the Utica and Marcellus shales.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

GPB Capital

Investor


Category Asset Manager
Founded 2013
PE ASSETS 1.5B USD
Size Large
Type Sector Agnostic
DESCRIPTION

GPB Capital is an asset management firm focused on acquiring income-producing private companies. Sectors of interest include automotive, retail, technology enabled services, waste management, and healthcare. GPB Capital was established in 2013 and is headquartered in New York City.


DEAL STATS #
Overall 7 of 11
Sector (Environmental) 3 of 3
Type (Buyout (LBO, MBO, MBI)) 4 of 7
State (Ohio) 1 of 1
Country (United States) 7 of 11
Year (2017) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-07-27 Staten Island Carting

Staten Island, New York, United States

Staten Island Carting, Inc. is a hauling company which currently operates five trucks that process approximately 815 tons of municipal solid waste and 165 tons of recycling per month in Staten Island, N.Y.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-01-18 Emmaus Life Sciences

Torrance, California, United States

Emmaus Life Sciences, Inc. is a developer of treatments and therapies for rare and orphan diseases. The company's research on sickle cell disease was initiated by Yutaka Niihara, MD, MPH, Chairman and CEO of Emmaus, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.

Buy -